Clinical trials: Immune Response
HIV Infections
Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children
Cohort I: The purpose of this study is to see how safe it is to combine 2 anti-HIV medications, efavirenz (EFZ) and nelfinavir (NFV) to treat HIV-positive children and to find an appropriate dose of EFZ to use in combination with…
- Trial name
- NCT00000893
- Testing
- Nelfinavir mesylate, Efavirenz
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 103 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bronchiolitis
Association of Dysbiosis and Immune Response in Bronchiolitis in Under 12 Months -Old Infants
Acute bronchiolitis is a common disease in children under the age of two, caused mainly by the respiratory syncytial virus (RSV).
- Trial name
- BRONCHOBIOTE (NCT06161285)
- Testing
- Sampling
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Pancreatitis
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase.
- Trial name
- NCT04195347
- Testing
- CM4620
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- St. Jude Children's Research Hospital
Systemic Lupus Erythematosus (SLE)
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response…
- Trial name
- BENCHMARK-SLE (NCT07175285)
- Testing
- Current standard of care treatment options
- Where
- 66 sites in United States, Argentina and 11 more
- Volunteers
- 223 people
- Sponsor
- Bristol-Myers Squibb
Tonsillitis, Hypertrophy
Immune Response To Intranasal Influenza Vaccination
This research during the last decade has focused on the kinetics of the systemic and local immune response to parenteral influenza vaccine in humans.
- Trial name
- NCT01866540
- Testing
- FLUENZ
- Where
- Norway
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Bergen
Healthy Infants, Mothers
Improving Rotavirus Vaccine Immune Response
Rotavirus is the leading cause of severe gastroenteritis in infants and young children worldwide and is estimated to account for 600,000 deaths in children <5 years of age. However, live oral enteric vaccines (e.g.
- Trial name
- NCT01825109
- Testing
- Rotavirus Vaccine & Breastfeeding
- Where
- Bangladesh
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Influenza Virus Vaccine Adverse Reaction, Influenza Vaccine Allergy
Immune Response and Risk of Side Effects After Influenza Vaccination in Athletes
Seasonal influenza vaccination was used to assess whether induction of immunity as well as the rate of side effects is influenced by the timing of the last training session before vaccination.
- Trial name
- NCT03654937
- Testing
- Influenza Vaccination
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Universität des Saarlandes
Cardiac Surgery
Epicardial Fat Immunity extRa Cellular vesicleS HearT
The FIRST study is a monocentric observational pilot study investigating the role of extracellular vesicles (EVs) derived from epicardial adipose tissue (EAT) in cardiovascular complications associated with obesity.
- Trial name
- FIRST (NCT07817667)
- Testing
- Epicardial adipose tissue biopsy, Thoracic subcutaneous adipose tissue biopsy
- Volunteers
- 100 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Atopic Dermatitis (AD), Autoantibody
Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis
Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as "self-reactive antibodies" or…
- Conditions
- Atopic Dermatitis (AD), Autoantibody, Auto-Immunity, Microbiome, Human
- Trial name
- DIANA (NCT07316465)
- Testing
- Development of atopic dermatitis with/without IgE autoantibodies
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Asthma, Lung Diseases
Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT
To examine the cellular and molecular mechanisms of corticosteroid and leukotriene receptor antagonists, focusing on their effects on T lymphocytes during both chronic (18 months) and acute therapy.
- Trial name
- NCT00021931
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematological Malignancies
Tissue Microarray of Hematological Malignancies
The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative…
- Trial name
- HemaTMA (NCT04142372)
- Where
- Finland
- Volunteers
- 5,000 people
- Sponsor
- Tampere University Hospital
Sepsis
Early PREdiction of Severe Sepsis I (ExPRES-Sepsis I) Study
Between 6 and 16% of patients presenting to hospital emergency departments have infections, with half of these having signs of systemic inflammation (known as 'sepsis').
- Trial name
- ExPRES (NCT02188992)
- Where
- 3 sites in United Kingdom
- Volunteers
- 401 people
- Sponsor
- University of Edinburgh
HIV Infections
Hepatitis B Vaccination (HBV) in HIV Infected Children
The purpose of this study is : To evaluate prevalence of protective hepatitis B antibody comparing intradermal (ID) and intramuscular (IM) route in antiHbsAb negative HIV infected children treated with highly active…
- Trial name
- NCT00886964
- Testing
- Intradermal HBV 1 course, Intramuscular HBV I course
- Where
- 2 sites in Thailand
- Volunteers
- 80 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study evaluated the pharmacokinetics (PK), safety, tolerability of and immune response to DTG when used concurrently with optimized background therapy…
- Trial name
- NCT01302847
- Testing
- DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
- Where
- 33 sites in United States, Botswana and 6 more
- Volunteers
- 181 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Peanut Allergy
A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.
- Trial name
- NCT03755713
- Testing
- ASP0892
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term…
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
- Trial name
- NCT00096460
- Testing
- Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy
- Where
- 30 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
HIV Infections, Hepatitis C
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study will evaluate how controlling HIV infection with HAART (highly active antiretroviral therapy) affects the response to hepatitis C treatment with peginterferon alpha-2b and ribavirin in HIV-infected patients with…
- Trial name
- NCT00031343
- Testing
- highly active antiretroviral therapy (HAART)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Ventilator-Associated Pneumonia
Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU)
Ventilator-associated pneumonia (VAP) is very common in the intensive care unit (ICU), affecting 9 to 40% of ICU patients and mortality rates range from 20 to 50% and may reach more than 70% when the infection is caused by…
- Trial name
- NCT00935285
- Where
- Greece
- Volunteers
- 300 people
- Sponsor
- University of Thessaly
Hand, Foot and Mouth Disease
Immunity and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China
This study evaluates three batches consistency, immunity duration and safety of inactivated Enterovirus 71(EV-A71) vaccine(vero cell) post-marketing among children aged 6-35months in China.3000 subjects will be recruited in this…
- Trial name
- NCT03893747
- Testing
- The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor, The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor, The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.